ArticleERJ open research2026
Comparing the effectiveness and safety of robotic-assisted bronchoscopy and computed tomography-guided transthoracic biopsy for evaluating pulmonary lung nodules: results from the DYSTRICT study.
Article in ERJ open research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Computed tomography-guided transthoracic biopsy (CTTB) and shape-sensing robotic-assisted bronchoscopy (ssRAB) are diagnostic modalities for evaluating high-risk pulmonary nodules. Previous studies have been limited by inconsistencies in defining diagnostic yield. The advent of strict diagnostic yield criteria enables a more accurate comparison of these modalities. The aim of this study was to compare the effectiveness and safety of ssRAB and CTTB in evaluating pulmonary nodules. Methods: DYSTRICT is a retrospective cohort including patients with high-risk pulmonary nodules who underwent ssRAB or CTTB between November 2022 and December 2024. A 1:1 matched analysis was performed based on nodule characteristics. Diagnostic yield was assessed using strict criteria, defining diagnostic lesions as those with a specific malignant or benign diagnosis. Associations between variables were analysed using descriptive statistics, and logistic models where appropriate. Results: A total of 574 nodules were evaluated (287 in each arm). Both groups had similar baseline characteristics, including age, sex, lesion size, nodule type and location. Strict diagnostic yield was comparable between ssRAB (n=213 (74%)) and CTTB (n=226 (79%)) (p=0.201). However, ssRAB demonstrated a significantly safer profile, with lower rates of pneumothorax (OR 0.04 (95% CI 0.01-0.08); p<0.001) and hospitalisation (OR 0.35 (95% CI 0.15-0.75); p=0.010) compared with CTTB. Conclusion: ssRAB and CTTB achieved comparable strict diagnostic yield rates in pulmonary nodules with similar baseline characteristics. However, ssRAB demonstrated a higher safety profile, with significantly lower rates of pneumothorax, chest tube placement and hospitalisation compared with CTTB.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.